Overview

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer

Status:
Recruiting

Trial end date:
2023-02-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to assess the efficacy, safety of MRG003 as single agent in EGFR-positive advanced non-small cell lung cancer

Phase:

Phase 2

Details

Lead Sponsor:

Shanghai Miracogen Inc.